Clinical trials
Breast Cancer Invasive clinical trials
Below are recruiting breast cancer invasive clinical trials, each written for real people, not researchers. We’re tracking 721 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT03019471Recruiting
Test for cancer using a noninvasive sample
This trial studies a noninvasive test to look for signs of cancer in people newly diagnosed with certain cancers. It aims to see whether the test can help detect or identify cancer before treatment starts.
Maastricht, LimburgAges 18 years+ - NCT06481956Enrolling by invitationPhase 2
T-DM1 plus a CDK4/6 inhibitor (ribociclib) for HER2-positive breast cancer
This clinical trial tests a combination of two targeted therapies for people with HER2-positive breast cancer that has spread or come back. The goal is to see if adding ribociclib to T-DM1 is safe and effective after other treatments have been used.
Hangzhou, ZhejiangAges 18–75 - NCT07180693Recruiting
Breast cancer that returns after CDK4/6 inhibitor treatment
This study looks at patients whose breast cancer returns after starting a CDK4/6 inhibitor (like abemaciclib or ribociclib) along with hormone therapy. The goal is to understand why the cancer comes back and find better ways to treat it.
Bergamo, ItalyAges 18 years+ - NCT02992574Recruiting
Radiation after mastectomy for certain node-negative breast cancers
This trial studies whether giving radiotherapy after a mastectomy helps prevent breast cancer coming back in women whose lymph nodes are not involved (or only very tiny spread). It may help reduce recurrence risk, especially for patients with higher-risk features despite node-negative early cancer.
Chandigarh, ChandigarhAges 18–80 - NCT03417622RecruitingPhase 3
Wide vs narrow breast surgery margins after lumpectomy
This study compares two ways of cutting the edge (margin) of tissue during lumpectomy after breast cancer treatment. It may help reduce the chance of the cancer coming back locally by testing whether a wider margin is better than a narrow one.
Al Mansurah, DKAges 18 years+ - NCT03561740RecruitingPhase 3
Capecitabine plus usual treatment for high-risk HER2 breast cancer
This trial looks at whether adding a chemotherapy medicine called capecitabine (taken in smaller, regular doses) to the standard after-surgery (adjuvant) treatment can lower the chance of cancer coming back in people with early-stage, high-risk HER2-positive breast cancer. It targets patients who still had cancer left after earlier treatment or who had higher-risk tumor features.
Guangzhou, GuangdongAges 18–70 - NCT04072653Recruiting
Sentinel node biopsy versus watchful waiting after PET
This trial studies whether taking a sample from the sentinel lymph node (a first lymph node that can be involved) improves care compared with observation, after a breast cancer PET scan of the armpit area. It may help people with certain early breast cancers avoid unnecessary procedures if the lymph nodes look negative on scans.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT04501523RecruitingPhase 2
ctDNA-guided immunotherapy boost after chemotherapy for triple-negative breast cancer
This Phase 2 study checks whether a blood test that looks for cancer DNA (ctDNA) can help decide who should get an extra 12-month immunotherapy treatment after standard chemotherapy and surgery. It may help reduce the chance of the cancer coming back in people with triple-negative breast cancer.
Guandong, GuangdongAges 18–80 - NCT04531696Recruiting
Post-death breast tissue donation study for cancer research
This trial invites adults with certain breast cancer conditions to donate tissue after death. Researchers hope the donated samples will help better understand cancer and improve future treatments.
LeuvenAges 18 years+ - NCT04614194RecruitingPhase 2
Blood and tumor markers to test response to abemaciclib
This trial studies how the immune system and other body signals in blood and tumor tissue relate to how well abemaciclib works before breast cancer surgery. The goal is to learn who benefits most from this medicine and why.
Dallas, TexasAges 18 years+ - NCT04803539RecruitingPhase 2/Phase 3
ctDNA-guided booster treatment after chemo for triple-negative breast cancer
This trial uses a blood test called ctDNA to see who is at higher risk after surgery and standard chemotherapy for triple-negative breast cancer. If your ctDNA test is positive, you may receive an extra “boost” treatment to help reduce the chance the cancer returns.
Guandong, GuangdongAges 18–80 - NCT04994067Recruiting
Registering radiation given during breast-conserving surgery
This study records details about radiation delivered while your surgery is happening for certain early breast cancers or pre-cancers. It may help doctors better understand who benefits most from this “intra-operative” radiation approach.
The Bronx, New YorkAges 18 years+ - NCT05192798RecruitingPhase 2
Albumin-bound chemo plus anti-blood-vessel drugs for TNBC
This Phase 2 study tests a chemotherapy called albumin-bound paclitaxel combined with medicines that block new blood vessel growth (antiangiogenic agents) for women with recurrent or metastatic triple-negative breast cancer. It aims to see whether this combination can better control cancer when it comes back or has spread.
Bengbu, AnhuiAges 18–80 - NCT05217966Recruiting
Radiation before possible breast surgery for early ER-positive cancer
This study gives radiation to the breast before surgery to see if some people can safely delay or even skip surgery. It targets women with a small, node-negative, ER-positive breast cancer with low genetic risk.
Montreal, QuebecAges 50 years+ - NCT05241119Recruiting
Lymph node mapping to guide surgery after chemotherapy
This study tests using a special carbon-based tracing method to help doctors check which lymph nodes to treat during surgery after you finish chemotherapy. It may improve how accurately the surgical plan targets cancer in the armpit (axillary) lymph nodes.
Shenyang, LiaoningAges 18–70 - NCT05291507RecruitingEarly Phase 1
MRI-guided focused ultrasound for breast cancer during surgery
This early study tests whether a device that uses focused ultrasound (guided by MRI) can be safely used during surgery for women with invasive breast cancer. It mainly looks at feasibility—whether the treatment can be delivered as planned and is safe.
Salt Lake City, UtahAges 18 years+ - NCT05341141Recruiting
Cold therapy plus compression to prevent nerve damage from chemo
This trial tests whether using cold therapy (cryotherapy) together with compression can lower the chance of numbness, tingling, or pain in the hands and feet caused by chemotherapy. It may help people planning chemotherapy for breast cancer stay more comfortable and function better.
Beijing, Beijing MunicipalityAges 20–70 - NCT05512286Recruiting
Radiation experience after breast surgery with belly flap
This trial looks at how people feel (patient-reported outcomes) and how safe treatment is when radiotherapy is given after a mastectomy with a DIEP belly skin-flap reconstruction. It may help doctors understand which experiences to expect and how to improve care.
Nanning, GuangxiAges 18 years+ - NCT05704166RecruitingPhase 2
Pirfenidone to prevent lung injury after breast radiation
This trial tests whether pirfenidone, a medication, can prevent acute lung injury caused by radiation therapy in people with breast cancer. You may be randomly assigned to pirfenidone or a placebo (inactive pill) to see which better protects the lungs during and after radiation.
Fuzhou, FujianAges 18–75 - NCT05708235RecruitingPhase 2
Using blood test results to guide breast cancer treatment
This Phase 2 study tests whether doctors can use a blood test (ctDNA) to find breast cancer recurrence risk early and guide further treatment. Depending on your ctDNA result and tumor markers, you may receive standard hormone therapy or one of several additional treatment options.
A CoruñaAges 18 years+ - NCT05749588RecruitingPhase 2
Study for advanced triple-negative breast cancer after prior treatments
This Phase 2 trial tests a treatment for people with triple-negative breast cancer that has come back or spread and has continued to progress despite earlier therapies. It may help by trying a new approach in patients who still have enough health to safely receive more treatment.
ShanghaiAges 18 years+ - NCT06050109Recruiting
Continuing Ovarian Suppression After 5 Years
This trial checks if staying on ovarian function suppression (OFS) therapy beyond 5 years helps prevent breast cancer from coming back. It's for women with early-stage, hormone-sensitive (HR+ HER2-) breast cancer who have already completed 5 years of OFS.
Wuhan, HubeiAges 18–60 - NCT06078384RecruitingPhase 2
Pembrolizumab and chemo for early-stage triple-negative breast cancer
This trial studies whether adding pembrolizumab (an immunotherapy) to standard chemotherapy after surgery can improve outcomes for people with early-stage triple-negative breast cancer. The treatment you receive depends on the level of immune cells (TILs) found in your tumor.
AmiensAges 18 years+ - NCT06097156Recruiting
Automated blood test for breast cancer monitoring
This trial tests an automated device that prepares blood samples to detect cancer-related changes. It aims to improve how doctors monitor breast cancer that has spread, without needing a tissue biopsy every time.
MilanAges 18 years+
Hear when a new Breast Cancer Invasive trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for breast cancer invasive?
- Yes. Clin2 currently lists 721 recruiting breast cancer invasive studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a breast cancer invasive trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a breast cancer invasive trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.